[Silence potentiates chemosensitivity of K562 cells to SAHA]

Hou-Cai Wang1, Jing Chen1, Na An1

  • 1State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.

Insights

Ribosomal protein S27a (RPS27a) inhibits apoptosis in chronic myeloid leukemia cells. Silencing RPS27a enhances K562 cell sensitivity to SAHA, increasing apoptosis and impacting cancer treatment strategies.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Biology

Background:

  • Ribosomal protein S27a (RPS27a) has known extra-ribosomal roles.
  • RPS27a is over-expressed in various cancers, including leukemia.
  • Its specific function in chronic myeloid leukemia (CML) requires further investigation.

Purpose of the Study:

  • To investigate the role of RPS27a in K562 CML cells.
  • To determine the effect of RPS27a silencing on K562 cell proliferation and apoptosis.
  • To assess the impact of RPS27a on sensitivity to suberoylanilide hydroxamic acid (SAHA).

Main Methods:

  • Short hairpin RNA (shRNA) was used to silence RPS27a in K562 cells.
  • Cell proliferation was assessed using the MTT assay.
  • Apoptosis was quantified by flow cytometry and morphological analysis after SAHA treatment.

Main Results:

  • RPS27a silencing decreased the IC50 of K562 cells to SAHA.
  • Silencing RPS27a significantly increased SAHA-induced apoptosis in K562 cells.
  • Morphological changes indicative of apoptosis were observed in silenced cells upon SAHA treatment.

Conclusions:

  • RPS27a inhibits apoptosis in K562 CML cells.
  • RPS27a knockdown potentiates the sensitivity of K562 cells to SAHA.
  • Targeting RPS27a may represent a therapeutic strategy to enhance leukemia treatment efficacy.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
816
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K